Back to Index
Etan Orgel, MD
Assistant Professor of Clinical Pediatrics
CHL 4650 W Sunset Blvd, Off Campus Los Angeles
+1 323 361 2121


Dr. Orgel is currently an attending physician on the Medical Supportive Care/Survivorship and Supportive Care Program and the Leukemia and Lymphoma Team within the Division of pediatric Hematology, Oncology, and Blood & Marrow Transplantation at the Children's Hospital Los Angeles (Los Angeles, CA). Dr. Orgel's clinical specialty focuses on higher risk and rare malignant hematology, and specifically, the rare phenomenon of Mixed-Phenotype Acute Leukemia (MPAL). He possesses an academic appointment as an Assistant Professor of Clinical Pediatrics in the Keck School of Medicine of the University of Southern California (USC) following strong training in general pediatrics from Children's National Medical Center (Washington, DC) and a pediatric hematology/oncology fellowship at CHLA. This was complemented with didactic clinical trial training via completing a Masters of Science in Clinical and Biomedical Investigations from the Department of Preventive Medicine at USC.

Dr. Orgel's primary research interest lies in the field of medical supportive care or "cancer control" (reducing acute and late treatment-related toxicities). His specific focus utilizes a translational research approach to target specific toxic effects to widen therapeutic windows for common chemotherapies and/or improve the quality of life of children with cancer. Currently, Dr. Orgel's active research encompasses studying new agents and novel strategies to reduce hearing loss from chemotherapy (cisplatin), to target obesity in pediatric ALL to improve survival, quality of life, and bone health, and to evaluate resistance to asparaginase (a highly-effective chemotherapy agent) in children with relapsed ALL.


Clinical Significance of Isolated Myeloperoxidase Expression in Pediatric B-Lymphoblastic Leukemia. Am J Clin Pathol. 2017 Mar 15. View in: PubMed

A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia. Leuk Lymphoma. 2017 Feb 20; 1-9. View in: PubMed

Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016 Nov; 63(11):1943-8. View in: PubMed

Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia. Bone. 2016 Apr; 85:131-7. View in: PubMed

Association of body mass index and survival in pediatric leukemia: a meta-analysis. Am J Clin Nutr. 2016 Mar; 103(3):808-17. View in: PubMed

Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy. Leuk Lymphoma. 2016 Jan 27; 1-8. View in: PubMed

Effect of Sensorineural Hearing Loss on Neurocognitive Functioning in Pediatric Brain Tumor Survivors. Pediatr Blood Cancer. 2015 Nov 3. View in: PubMed

Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia. Pediatr Infect Dis J. 2015 Apr; 34(4):e78-84. View in: PubMed

Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood. 2014 Dec 18; 124(26):3932-8. View in: PubMed

Impact on Survival and Toxicity by Duration of Weight Extremes During Treatment for Pediatric Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2014 May 1; 32(13):1331-7. View in: PubMed

Efficacy and tolerability of intravenous pentamidine isethionate for pneumocystis jiroveci prophylaxis in a pediatric oncology population. Pediatr Infect Dis J. 2014 Mar; 33(3):319-21. View in: PubMed

Infectious morbidity by catheter type in neutropenic children with cancer. Pediatr Infect Dis J. 2014 Mar; 33(3):263-6. View in: PubMed

Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective. Pediatr Blood Cancer. 2013 Sep; 60(9):1528-33. View in: PubMed

The links between insulin resistance, diabetes, and cancer. Curr Diab Rep. 2013 Apr; 13(2):213-22. View in: PubMed

Murphy D, Orgel E, Termuhlen A, Shannon S, Warren K, Quinn GP. Why Healthcare Providers Should Focus on the Fertility of AYA Cancer Survivors: It's Not Too Late! Front Oncol. 2013; 3:248. View in: PubMed

Why Healthcare Providers Should Focus on the Fertility of AYA Cancer Survivors: It's Not Too Late! Front Oncol. 2013; 3:248. View in: PubMed

Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer. 2012 Jun; 58(6):953-8. View in: PubMed

A failing medical educational model: a self-assessment by physicians at all levels of training of ability and comfort to deliver bad news. J Palliat Med. 2010 Jun; 13(6):677-83. View in: PubMed

Powered bySC CTSI